Share this article on:

Diagnosis of Nonalcoholic Fatty Liver Disease in Children and Adolescents: Position Paper of the ESPGHAN Hepatology Committee

Vajro, Pietro*; Lenta, Selvaggia; Socha, Piotr; Dhawan, Anil§; McKiernan, Patrick||; Baumann, Ulrich#; Durmaz, Ozlem**; Lacaille, Florence††; McLin, Valerie‡‡; Nobili, Valerio

Journal of Pediatric Gastroenterology & Nutrition: May 2012 - Volume 54 - Issue 5 - p 700–713
doi: 10.1097/MPG.0b013e318252a13f
Consensus Statement

ABSTRACT: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in children and adolescents in the United States, and most probably also in the rest of the industrialized world.

As the prevalence of NAFLD in childhood increases with the worldwide obesity epidemic, there is an urgent need for diagnostic standards that can be commonly used by pediatricians and hepatologists. To this end, we performed a PubMed search of the adult and pediatric literature on NAFLD diagnosis through May 2011 using Topics and/or relevant Authors as search words. According to the present literature, NAFLD is suspected based on the association of fatty liver combined with risk factors (mainly obesity), after the exclusion of other causes of liver disease. The reference but imperfect standard for confirming NAFLD is liver histology. The following surrogate markers are presently used to estimate degree of steatosis and liver fibrosis and risk of progression to end-stage liver disease: imaging by ultrasonography or magnetic resonance imaging, liver function tests, and serum markers of liver fibrosis.

NAFLD should be suspected in all of the overweight or obese children and adolescents older than 3 years with increased waist circumference especially if there is a NAFLD history in relatives. The typical presentation, however, is in children ages 10 years and older. The first diagnostic step in these children should be abdominal ultrasound and liver function tests, followed by exclusion of other liver diseases. Overweight/obese children with normal ultrasonographic imaging and normal liver function tests should still be monitored due to the poor sensitivity of these tests at a single assessment.

Indications for liver biopsy include the following: to rule out other treatable diseases, in cases of clinically suspected advanced liver disease, before pharmacological/surgical treatment, and as part of a structured intervention protocol or clinical research trial.

*Department of Pediatrics, Medical School, University of Salerno, Salerno, Italy

Department of Pediatrics, University of Naples “Federico II,” Naples, Italy

Department of Gastroenterology, Hepatology, and Eating Disorders, the Children's Memorial Health Institute, Warsaw, Poland

§Liver Unit, King's College, London

||Liver Unit, Birmingham Children's Hospital, Birmingham, UK

Hepatometabolic Unit, “Bambino Gesù” Children's Hospital, Rome, Italy

#Division of Pediatric Gastroenterology and Hepatology, Hannover Medical School, Hannover, Germany

**Department of Pediatrics, Istanbul Medical Faculty, University of Istanbul, Turkey

††Hopital Necker-Enfants Malades, Paris, France

‡‡Department of Pediatrics, University of Geneva Hospital, Geneva, Switzerland

Address correspondence and reprint requests to Pietro Vajro, MD, Chair of Pediatrics, University of Salerno, Via Allende, 84081 Baronissi (Salerno), Italy (e-mail: e-mailpvajro@unisa.it)

Received 6 December, 2011

Accepted 23 February, 2012

Drs Vajro, Socha, Dhawan, McKiernan, and Nobili are members of the NAFLD Group of the ESPGHAN Hepatology Committee. Drs Baumann, Durmaz, Lacaille, and McLin are other members of the ESPGHAN Hepatology Committee. Dr Lenta is an invited expert participating in this ESPGHAN panel.

Conflicts of interest for the writing group appear on the ESPGHAN Web site (www.espghan.med.up.pt).

Copyright 2012 by ESPGHAN and NASPGHAN